Additional adverse drug reaction reports have also been received, prompting professional bodies to recommend immediate caution until more information becomes available. In its nationwide advisory released on June 29, APSA stated that the volume of reported incidents warranted proactive action in the interest of patient safety.
The association is conducting a detailed review that includes verification of reported cases, assessment of batch numbers, evaluation of storage and handling practices, and coordination with regulatory authorities and the manufacturer. As part of the interim recommendations, APSA has advised hospitals and anesthesiologists to remove the product from clinical use, isolate existing inventory, document key product information such as batch numbers, manufacturing and expiry dates, and storage conditions, and promptly report any suspected adverse events with complete…
